United Therapeutics Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From United Therapeutics Corporation
Meeting all primary and secondary endpoints in a pair of pivotal trials, Brickell says sofpironium bromide gel will be ready for FDA filing in mid-2022. The topical is already approved in Japan as Ecclock.
The UK firm has not completed a clinical trial yet but having raised over $350m from its NASDAQ initial public offering and an extra $160m from a private placement, Exscientia's future looks extremely bright.
User fee goal dates are coming up in October for more than 15 applications, according to the Pink Sheet’s US FDA Performance Tracker.
US government moves ahead with enforcement action while several court decisions remain pending on the viability of its interpretation of the law governing the 340B outpatient drug discount program. Underscoring industry’s confidence in its opposing view, Merck & Co. recently joined the companies that are restricting discounts to contract pharmacies.
- Large Molecule
- Other Names / Subsidiaries
- Lung Biotechnology PBC
- Lung Rx, Inc.
- SteadyMed Ltd.
- SteadyMed Therapeutics, Inc.
- Unither Pharmaceuticals
- Unither Virology